Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Donald E Mager

Showing results (61-70 of 163) with videos related to

Pageof 17
Sort By:
Cancer Research|February 22, 2012
Combinatorial chemotherapeutic efficacy in non-Hodgkin lymphoma can be predicted by a signaling model of CD20 pharmacodynamicsJohn M Harrold, Robert M Straubinger, Donald E Mager
The Journal of Pharmacology and Experimental Therapeutics|November 2, 2012
Systems pharmacological analysis of paclitaxel-mediated tumor priming that enhances nanocarrier deposition and efficacySihem Ait-Oudhia, Robert M Straubinger, Donald E Mager
Journal of Pharmacokinetics and Pharmacodynamics|January 8, 2018
Boolean network modeling in systems pharmacologyPeter Bloomingdale, Van Anh Nguyen, Jin Niu, et al.
The AAPS Journal|March 25, 2011
Physiologically based pharmacokinetic model of amphotericin B disposition in rats following administration of deoxycholate formulation (Fungizone®): pooled analysis of published dataLeonid Kagan, Pavel Gershkovich, Kishor M Wasan, et al.
The Journal of Pharmacology and Experimental Therapeutics|April 22, 2010
Type I interferon receptor is a primary regulator of target-mediated drug disposition of interferon-beta in miceAnson K Abraham, Leonid Kagan, Sarmishtha Kumar, et al.
Pharmaceutical Research|June 25, 2013
Dual physiologically based pharmacokinetic model of liposomal and nonliposomal amphotericin B dispositionLeonid Kagan, Pavel Gershkovich, Kishor M Wasan, et al.
Cancer Chemotherapy and Pharmacology|March 23, 2019
Rituximab dosing in hematological malignancies: an old question, revisitedPeter N Morcos, Axel Boehnke, Nancy Valente, et al.
Toxicological Sciences : an Official Journal of the Society of Toxicology|May 26, 2010
Pharmacokinetics and toxicodynamics of pralidoxime effects on paraoxon-induced respiratory toxicityPascal Houzé, Donald E Mager, Patricia Risède, et al.
The Journal of Pharmacology and Experimental Therapeutics|June 17, 2004
Exendin-4 pharmacodynamics: insights from the hyperglycemic clamp techniqueDonald E Mager, Darrell R Abernethy, Josephine M Egan, et al.
Journal of Pharmaceutical Sciences|April 25, 2003
Comparative pharmacokinetics of coumarin anticoagulants L: Physiologic modeling of S-warfarin in rats and pharmacologic target-mediated warfarin disposition in manGerhard Levy, Donald E Mager, Wing K Cheung, et al.
Pageof 17

Showing results (61-70 of 163) with videos related to

Sort By:
Pageof 17
Cancer Research|February 22, 2012
Combinatorial chemotherapeutic efficacy in non-Hodgkin lymphoma can be predicted by a signaling model of CD20 pharmacodynamicsJohn M Harrold, Robert M Straubinger, Donald E Mager
The Journal of Pharmacology and Experimental Therapeutics|November 2, 2012
Systems pharmacological analysis of paclitaxel-mediated tumor priming that enhances nanocarrier deposition and efficacySihem Ait-Oudhia, Robert M Straubinger, Donald E Mager
Journal of Pharmacokinetics and Pharmacodynamics|January 8, 2018
Boolean network modeling in systems pharmacologyPeter Bloomingdale, Van Anh Nguyen, Jin Niu, et al.
The AAPS Journal|March 25, 2011
Physiologically based pharmacokinetic model of amphotericin B disposition in rats following administration of deoxycholate formulation (Fungizone®): pooled analysis of published dataLeonid Kagan, Pavel Gershkovich, Kishor M Wasan, et al.
The Journal of Pharmacology and Experimental Therapeutics|April 22, 2010
Type I interferon receptor is a primary regulator of target-mediated drug disposition of interferon-beta in miceAnson K Abraham, Leonid Kagan, Sarmishtha Kumar, et al.
Pharmaceutical Research|June 25, 2013
Dual physiologically based pharmacokinetic model of liposomal and nonliposomal amphotericin B dispositionLeonid Kagan, Pavel Gershkovich, Kishor M Wasan, et al.
Cancer Chemotherapy and Pharmacology|March 23, 2019
Rituximab dosing in hematological malignancies: an old question, revisitedPeter N Morcos, Axel Boehnke, Nancy Valente, et al.
Toxicological Sciences : an Official Journal of the Society of Toxicology|May 26, 2010
Pharmacokinetics and toxicodynamics of pralidoxime effects on paraoxon-induced respiratory toxicityPascal Houzé, Donald E Mager, Patricia Risède, et al.
The Journal of Pharmacology and Experimental Therapeutics|June 17, 2004
Exendin-4 pharmacodynamics: insights from the hyperglycemic clamp techniqueDonald E Mager, Darrell R Abernethy, Josephine M Egan, et al.
Journal of Pharmaceutical Sciences|April 25, 2003
Comparative pharmacokinetics of coumarin anticoagulants L: Physiologic modeling of S-warfarin in rats and pharmacologic target-mediated warfarin disposition in manGerhard Levy, Donald E Mager, Wing K Cheung, et al.
Pageof 17